本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Enanta Pharmaceuticals Inc.

12.96
+0.26002.05%
盤後12.960.00000.00%19:30 EDT
成交量:28.91萬
成交額:372.10萬
市值:3.76億
市盈率:-5.53
高:13.04
開:12.83
低:12.59
收:12.70
52周最高:17.15
52周最低:7.05
股本:2,901.85萬
流通股本:2,251.30萬
量比:1.27
換手率:1.28%
股息:- -
股息率:- -
每股收益(TTM):-2.3416
每股收益(LYR):-3.8381
淨資產收益率:-70.12%
總資產收益率:-12.28%
市淨率:3.72
市盈率(LYR):-3.38

資料載入中...

2024/05/08

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/05/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/06

重要事件披露

Form 8-K - Current report
2024/03/12

重要事件披露

Form 8-K - Current report
2024/02/15

SEC問詢函

Form CORRESP - Correspondence
2024/02/14

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/02/07

重要事件披露

Form 8-K - Current report
2024/02/06

SEC問詢函

Form CORRESP - Correspondence
2024/01/26

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/12

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/12/27

重要事件披露

Form 8-K - Current report
2023/12/13

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/11/23

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/11/20

重要事件披露

Form 8-K - Current report
2023/11/16

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/08/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/08

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/08/07

重要事件披露

Form 8-K - Current report